Original Research
Accepted on 18 Nov 2025
The Long-Term Avoided Recurrences and Recurrence-Related Cost of Alectinib for Postoperative Adjuvant Therapy in Chinese Patients with Early-Stage ALK-Positive Non-Small Cell Lung Cancer
in Health Economics
- 134 views